香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內 容 概 不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不對因本公告全部或任何部份內容而產生或因倚賴該等內容而引致之 任 何 損 失 承 擔 任 何 責 任。 HealthyWay Inc. 健康之路股份有限公司 （於 開 曼 群 島 註 冊 成 立 的 有 限 公 司） （股 份 代 號：2587） 內幕消息 正面盈利預告 本 公 告 乃 由 健 康 之 路 股 份 有 限 公 司（「本公司」），連 同 其 附 屬 公 司 統 稱（「本 集 團」）根 據 香 港 聯 合 交 易 所 有 限 公 司 證 券 上 市 規 則（「上市規則」）第13.09(2) (a)條及香港法例第571章證券及期貨條例第XIVA部內幕消息條文而作出。 本 公 司 董 事 會（「董事會」）謹 此 知 會 本 公 司 股 東 及 潛 在 投 資 者，根 據 對 本 集團截至2025年12月31日 止 年 度（「2025年 度」）的 最 新 未 經 審 核 綜 合 管 理 賬 目 及 目 前 可 得 的 其 他 資 料 ...

Group 1 - The core point of the article highlights that southbound funds increased their holdings in Health Road (02587.HK) by 306,000 shares on February 10, indicating a positive trend in investment interest [1] - Over the past five trading days, there were three days of net reductions in holdings by southbound funds, totaling a net decrease of 1.9745 million shares [1] - In the last 20 trading days, southbound funds increased their holdings on 16 days, with a cumulative net increase of 10.576 million shares [1] Group 2 - As of now, southbound funds hold 191 million shares of Health Road, accounting for 21.75% of the company's total issued ordinary shares [1] - Health Road Holdings Limited primarily engages in providing enterprise services, digital marketing services, and health care services as an investment holding company [1] - The company operates its business through three segments: enterprise services and digital marketing services, health care services, and other health services and products sold through various online and offline channels [1]

Group 1 - Yang Mingchao, the founder of Guoquan, has officially joined Songhe Liquor Industry as the chairman and director, completing all business registration procedures [1][3] - Yang has been managing Songhe Liquor for over a year and has invested 180 million yuan to buy two years of development time for the company [3] - Guoquan Industrial Development Co., Ltd. holds 51.81% of Songhe Liquor's shares, and Yang controls this company, which is not directly related to the listed company Guoquan Foods [3] Group 2 - On February 4, the same day as the management change, Guoquan Foods announced plans to purchase up to 200 million yuan worth of liquor products from its affiliate, Songhe, to further develop the "Songhe Liquor Delivery" service [5] - The management team of Songhe Liquor now includes six members, with several coming from the Guoquan team, including Wang Shuiyun and Li Jinzhi [7] - Songhe Liquor's registered capital has been increased to 2 billion yuan, indicating a significant financial commitment to its operations [8]

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2026年1月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 健康之路股份有限公司 呈交日期: 2026年2月4日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02587 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 2,500,000,000 | USD | | 0.00002 | USD | | 50,000 | | 增加 / 減少 (-) | | | 0 | | | | USD | | | | 本月底結存 | | | 2,500,000,000 | USD | | 0.00002 | USD | | 50,000 | 本月底法定/註冊股本 ...

Core Viewpoint - Health Road (02587.HK) has entered the cell therapy sector through a strategic partnership with He Yuan Bio (688238.SH), marking a significant step in building a comprehensive health service ecosystem and demonstrating its intent to rapidly position itself in the industry using a light-asset model [1][2]. Group 1: Differentiated Strategy - The industry is witnessing significant investments, such as ByteDance's 6 billion yuan commitment to a medical complex, highlighting the value of the cell therapy sector [2]. - Health Road adopts a pragmatic approach by leveraging regional agents and ecosystem collaboration, contrasting with the heavy asset investment strategies of industry giants [2]. - He Yuan Bio, a listed company on the Sci-Tech Innovation Board, has established an integrated platform for research, production, and application in cell and gene therapy, showcasing strong industrial capabilities and technical reserves [2]. Group 2: Business Model and Financial Performance - Health Road's proactive business structure optimization has led to an increase in gross margin to 31.2%, indicating improved profitability [3]. - The cell storage and preparation business typically features high gross margins and prepayment characteristics, which will further enhance the company's revenue structure and provide stable cash flow [3]. - With the cell therapy market growing at an annual rate exceeding 50%, this strategic positioning opens new growth avenues for the company [3]. Group 3: Ecosystem Synergy - The new cell therapy business can quickly integrate with Health Road's existing network of over 11,000 medical institutions, enhancing customer loyalty and service value [4]. - The company can leverage its 211.8 million registered users to introduce innovative product combinations, such as "cell storage + health assessment" and "exosome anti-aging + medical health services," maximizing user lifecycle value [4]. - By designing innovative products like "insurance + cell therapy" for partners in insurance and banking, the company can further extend its service chain [4]. Group 4: Strategic Positioning - Health Road's entry into the cell biotechnology sector represents a forward-looking strategic positioning, utilizing a light-asset and strong synergy model to tap into a high-growth market [4]. - This approach minimizes the risks associated with heavy R&D investments while maximizing the use of existing ecosystem advantages [4]. - As the business gradually takes shape and the model is validated, Health Road is expected to carve out a unique path in the cell therapy field, creating sustainable growth value for investors [4].

Core Insights - The cell therapy market is experiencing rapid growth, with an average annual growth rate exceeding 50%, and is expected to reach a market size of 58.4 billion yuan by 2030 [1] - The implementation of the new regulations for biomedical technology clinical research and application, effective from May 1, 2026, is seen as a foundational law for the industry, promoting a shift towards a comprehensive health management approach [1] Group 1: Company Strategy - Health Road has entered the cell therapy sector through a strategic partnership with He Yuan Bio, indicating its intent to build a comprehensive health service ecosystem [1][2] - The company adopts a light-asset model, focusing on regional agency as a practical approach to accelerate its growth in the cell therapy market [2] - Health Road's collaboration with He Yuan Bio, a company with a robust integrated platform in cell and gene therapy, enhances its industrial capabilities and technological reserves [2] Group 2: Market Positioning - Health Road has established a vast network with 211.8 million registered users and 905,000 registered doctors, allowing it to leverage its existing resources for rapid business expansion [2][4] - The company is focusing on three core areas: cell storage, cell preparation, and exosome preparation, aligning with its comprehensive health service system [2] - The cell storage and preparation business typically has high gross margins and prepayment characteristics, which will further optimize the company's revenue structure and provide stable cash flow [3] Group 3: Competitive Advantage - Health Road's ecosystem enables it to quickly form multi-dimensional synergies, enhancing customer loyalty and service value through its network of over 11,000 medical institutions [4] - The company can introduce innovative product combinations to its vast user base, maximizing user lifecycle value [4] - By leveraging existing resources, Health Road can achieve rapid expansion without the need to build clinical channels and user trust from scratch [4]

Group 1: Retail Developments - JD Fresh opened two new stores in Beijing and Shanghai, focusing on 24-hour fresh products and private label gift boxes, attracting significant customer interest during the New Year season [1] - Starbucks plans to open at least four new stores in Hong Kong within the next six months, capitalizing on the recovery of the local economy and increased foot traffic [4] - Yonghui Supermarket's Beijing Hongkun Plaza store has officially resumed operations, ensuring sufficient product supply and staff readiness [3] Group 2: Company Performance Forecasts - Wanchen Group anticipates a substantial increase in revenue for 2025, projecting between 50 billion to 52.8 billion yuan, with net profit expected to rise by 319.05% to 376.97% year-on-year [6] - Three Squirrels expects a significant decline in net profit for 2025, forecasting a drop of 57.08% to 66.89% due to structural issues during the sales peak and rising raw material costs [7] - Encountering a positive outlook, "Encounter Little Noodles" predicts a net profit of 100 million to 115 million yuan for 2025, marking a growth of 64.7% to 89.5% compared to 2024 [8] Group 3: Market Trends and Strategies - Maimai Hen Mang's CEO emphasized that the growth potential in the snack retail sector far exceeds existing competition, focusing on untapped markets in lower-tier cities [4] - Dali Food is leading the New Year gift box market by leveraging its core competitiveness and effective supply chain management, ensuring high demand and quick product turnover [8] - Zara has closed five stores in mainland China, reducing its presence to 59 stores, reflecting a strategic retreat from rapid expansion [10]

点评：东方甄选在经历管理层更迭与业务调整后，呈现出营收稳步修复、盈利能力企稳的态势。不过， 在竞争加剧的市场环境下，公司也需要考虑未来增长面临的挑战：如何在线下旗舰店等新业务探索与线 上核心业务之间取得平衡，并建立起不依赖于单一IP的持续内容与产品创新能力，这些都是其从阶段性 企稳迈向长期增长的关键。 ｜ 2026年1月29日星期四 ｜ NO.1 东方甄选公布2026财年中期财报 1月28日，东方甄选公布了2026财年中期业绩。2025年6月1日至11月30日，公司总营收23亿元，同比增 长5.7%。若剔除2025财年上半年分拆前产生的部分收入，东方甄选报告期内的总营收同比增加17%。报 告期内，东方甄选净溢利达2.39亿元。在渠道布局方面，东方甄选透露，除在北京设立首家线下体验店 外，还计划开设新的矩阵直播账号并招募新主播，以增强公司的品牌影响力。 点评：阿里云将开源AI助手转化为标准化云服务，试图通过整合自身算力、模型与办公生态，降低用 户部署和使用智能体的技术门槛与前期成本，为其实际业务场景的试用铺平道路。 NO.3 锅圈组建AI事业部 1月28日，锅圈食品宣布，组建独立的AI事业部，聚焦在家吃饭场景， ...

健康之路(02587)发布公告，于2026年1月28日，该公司斥资386.48万港元回购78万股股份，每股回购价 4.92-4.98港元。 ...

格隆汇1月28日丨健康之路(02587.HK)公告，1月28日耗资386.5万港元回购78万股。 ...